|All Peptides

Pinealon

Last reviewed: June 3, 2026 by The Peptide Catalog Team

A Khavinson tripeptide (Glu-Asp-Arg / EDR) marketed as a neuroprotective brain peptide; evidence is preclinical cell-culture and rodent only, with no human trials. A Khavinson short-peptide bioregulator (tripeptide Glu-Asp-Arg / EDR) studied in preclinical cell and rodent models for neuroprotection and cognition.

Overview

Pinealon Results Timeline

Progression
1
Days 1–3
Physical Changes
No reliable early-effect data; mechanism is not acute stimulation
Performance & Recovery
Any same-day change reported is anecdotal and unverified
Other Benefits
No human timeline exists for Pinealon
2
Days 4–10
Physical Changes
Active dosing window in the community short-course model
Performance & Recovery
Closest anchor is in-vitro ROS reduction — not a human felt effect
Other Benefits
Subjective change here is anecdote, not measured data
3
Days 11–20
Physical Changes
Rodent learning data is the only 'outcome over time' signal
Performance & Recovery
Animal model result — does not predict human cognitive change
Other Benefits
Whether anything persists after stopping is unknown in humans
4
Honest read
Physical Changes
"No noticeable change" is fully consistent with the evidence
Performance & Recovery
Preclinical only; no clinical efficacy trial, no FDA evaluation
Other Benefits
A research peptide — set expectations accordingly

Timeline is illustrative and non-guaranteed. Outcomes vary and are commonly discussed alongside training, nutrition, sleep, and cycling practices.

Read the full Pinealon results timeline →

How It WorksShort-Peptide Bioregulator — Neuro / Epigenetic (Preclinical Evidence Only)

Target → Signal → Effect → Outcomes

1
Target

Neuronal Chromatin / Gene Promoters

Pinealon is the tripeptide Glu-Asp-Arg(EDR), one of the short "peptide bioregulators" from the Khavinson research program. The leading hypothesis is that this small, charged peptide enters the cell and interacts with promoter regions of specific genes — a proposed epigenetic mechanism modeled in docking and cell-culture work, not confirmed in humans.

2
Cellular Signal

Reduced Oxidative Stress & Apoptosis

In cultured neurons under oxidative stress, Pinealon produced a dose-dependent reduction in reactive-oxygen-species accumulation and decreased necrotic cell death. Mechanistic papers model it as nudging transcription of neuroprotective and apoptosis-related genes. These are in-vitro and modeling findings — a plausible cellular signal, not a validated human pathway.

3
Systemic Effect

Neuroprotection (Animal Models)

The closest thing to a whole-organism effect is rodent: in offspring exposed to prenatal oxidative stress, Pinealon administration was associated with improved spatial learning and lower neuronal oxidative stress. That is a developmental animal model — there is no human systemic outcome data at all.

4
What You Notice

Unknown in Humans

Honestly, there is no human evidence to predict what a person would notice. The measured effects were cellular and behavioral in animals, not subjective human experiences. "No perceptible change" is fully consistent with the absence of human efficacy data.

What Makes This Peptide Different

Pinealon is not a validated drug — it is a research tripeptidefrom the Khavinson bioregulator framework, marketed as a neuroprotective "brain peptide." What distinguishes it is the proposed epigenetic mechanism (a short peptide acting at gene promoters) — an intriguing idea backed mostly by cell-culture and rodent work from a single group, with no human trials, no FDA evaluation, and no established dose.

Top Pinealon Vendors

Dosing ProtocolNeuroprotection (Research / No Human Data)

Educational reference only. Individual responses vary. Consult healthcare provider before use.

Vial Size
10 mg
Reconstitution
1 ml BAC water (10 mg/ml)
Dose
5-10 mg (50-100 units) — community convention, not a trial dose
Timing
AM
Frequency
Once daily
Duration
Short 10-20 day courses (community convention)
Protocol Notes
Khavinson tripeptide bioregulator (Glu-Asp-Arg / EDR). There is no human-trial dose — figures shown are community conventions anchored to the single 10mg vial size. Evidence is preclinical cell-culture and rodent only.

Why This Dosing Protocol

What dose do people use? The 5-10 mg/day figures circulating online are community conventions anchored to the single 10 mg vial size, not trial-derived numbers.

Why short courses? Community use mirrors the short-pulse administration of Khavinson-program bioregulators in preclinical work — convention by analogy, not a tested Pinealon protocol.

Reconstitution Calculator

Dilution math and unit conversions. Prefilled using a common vial size for this peptide.

Open calculator

Storage & Handling

Storage at a glance

Proper storage temperatures, shelf life, reconstitution best practices, and travel tips for lyophilized and reconstituted peptides.

Powder: Freezer
1+ year at -20°C
Reconstituted: Fridge
4 weeks max at 2-8°C
View Complete Storage Guide

Handling specifics

Educational overview on storage, labeling, and traceability considerations for lab environments. Consult primary literature and vendor documentation for specifics.

Powder storage (very stable)
  • Freezer (-20°C): 1+ year
  • Refrigerator (2-8°C): 1-3 months
  • Room temperature: 2-3 weeks (emergency only)
Reconstituted storage (fragile)
  • MUST refrigerate at 2-8°C
  • 4-week maximum shelf life
  • NEVER freeze after reconstitution
  • Use bacteriostatic water for multi-dose

FAQ

What is Pinealon (EDR)?

Pinealon is a synthetic tripeptide — Glu-Asp-Arg, also written EDR — from the Russian "peptide bioregulator" research program associated with Vladimir Khavinson. It is marketed as a neuroprotective brain peptide. In preclinical work it reduced reactive oxygen species and neuronal cell death and was modeled as a regulator of gene expression. There are no human clinical trials, no FDA evaluation, and no established dose.

How strong is the evidence behind Pinealon?

Thin and early. The published data is preclinical — cell-culture and rodent studies — and most of it comes from a single research group. A 2011 study reported reduced ROS and necrotic cell death in neurons (Khavinson et al.), and a 2012 rodent study reported improved learning in offspring exposed to prenatal oxidative stress (Arutjunyan et al.). No human trial has confirmed any cognitive or neuroprotective benefit in people.

Is there a proven Pinealon dose?

No. Because there are no human trials, there is no validated dose. Community protocols describe roughly 5-10 mg per day subcutaneously in short 10-20 day courses, but those figures are conventions shaped by the single 10 mg vial size — not dose-finding data.

Does Pinealon improve sleep, like its 'pineal' name suggests?

There is no human evidence that Pinealon improves sleep or melatonin rhythms. Despite the name, the published research centers on neuronal oxidative stress and gene-expression modeling, not sleep architecture. Any sleep claim is unsupported by the available data.

How long does reconstituted peptide last?

Once mixed with bacteriostatic water, peptides remain stable for up to 4 weeks when refrigerated at 2-8°C (36-46°F). Unopened powder can last 1+ year in the freezer. Get our complete Storage & Travel Guide.

Is this peptide legal to purchase?

Peptides sold "for research purposes only" are legal to purchase in the US, but are not FDA-approved for human use outside of specific medical applications. Always consult a healthcare provider before use.

New to peptides?

Take our Peptide Match tool to find the best peptide for your goals. You can also read our Complete Guide to Peptides to learn the basics.

Pinealon Research Articles

Disclosure: we may earn affiliate commission from qualifying purchases. Educational information only — not medical advice.